Clinical Trial Update: Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating divalproex sodium for the cutaneous manifestations of systemic sclerosis (scleroderma) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• DIVALPROEX SODIUM (divalproex sodium)

Snippet

Sponsor: Yale University | Conditions: Scleroderma, Systemic Sclerosis | Phase 1, Phase 2 | Status: WITHDRAWN